Morgan Stanley Reiterates Overweight on Eli Lilly (LLY), Cites Growth Potential of New Platform

Eli Lilly & Company (NYSE:LLY) ranks among the best high profit margin stocks to buy. Following the reveal of an innovative employer access platform for obesity therapies, Morgan Stanley reiterated its Overweight rating and $1,313 price target for Eli Lilly & Company (NYSE:LLY) on March 5. Eli Lilly recently established its Employer Connect platform in the US, which provides flexible benefit designs geared at increasing access to obesity treatments like Zepbound. Pixabay/Public Domain In order to produc ...